NCT05849727

A Clinical Study of TQH3821 Tablets in the Treatment of Treated Rheumatoid Arthritis

Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Trial to Evaluate the Efficacy and Safety of TQH3821 Tablets in Patients With Treated Rheumatoid Arthritis

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 195 (actual)
• Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy and safety of TQH3821 in treated patients with moderate-to-severe active rheumatoid arthritis.

Conditions

• Rheumatoid Arthritis

Interventions

Type	Name	Description
DRUG	TQH3821 tablets 200 mg	TQH3821 is a Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) inhibitor.
DRUG	TQH3821 tablets matching placebo	TQH3821 tablets matching placebo without active substance.

Timeline

• Start date: 2023-08-30
• Primary completion: 2025-01-15
• Completion: 2025-01-15
• First posted: 2023-05-09
• Last updated: 2025-02-20

Locations

34 sites across 1 country: China